Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00653536Phase 1Withdrawn

A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke

Role: collaborator

NCT00119717Phase 3Completed

Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)

Role: lead

NCT01006993Phase 1Completed

Feasibility and Safety of NeuroFlo in Stroke Patients Receiving Tissue Plasminogen Activator

Role: lead

NCT00436592Phase 1Completed

Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients

Role: lead

All 4 trials loaded